Select your language

Other official information and services: www.belgium.be  belgium

  • Key figures
  •  Data
  • Graphics
  • Comments
PRESCRIBERS
Main prescribers: General practitioners 65.14%
INSURED CONSUMERS
% of insured consumers 20.72%
Median age 42 years
Max/min ratio of the median age (by district) 1.45
Percentage of women 53.19%
Ratio Preferential scheme/General scheme 1.13
Coefficient of variation (2022) 13.13
Max/min ratio of % of insured consumers (by district) 1.63
CONSUMPTION
Annual consumption (DDD) 36,261,779
Consumption of DDD (per 100,000 insured persons) 316,197.03
% DDD issued outside the insurance (approximate) 2.52%
Average annual consumption per insured consumer (DDD) 15.26
% of insured consumers with > 3 times the average consumption 2.55%
Coefficient of variation (% of insured consumers) 2012-2014 10.61
Coefficient of variation (% of insured consumers) 2020-2022 12.05
Trend 2012-2022 -2.47%
Trend 2012-2019 -2.03%
Trend 2019-2022 -3.47%
DIRECT EXPENDITURE (DDD)
Annual expenditure charged to the insurance 25,416,719
Average annual expenditure per insured person 2.22
Average patient share per insured consumer 39.28%
Max/min ratio of expenditure per insured person (by disctrict) 1.80
% “Low-cost” medication 99.99%
Trend 2012-2022 -6.48%
Trend 2019-2022 -2.51%


On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

CODES (ATC-5) LABELS
J01CA PENICILLINS WITH EXTENDED SPECTRUM
J01CR COMBINATIONS OF PENICILLINS, INCL. BETA-LACTAMASE INHIBITORS

The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.

Click below to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.

Antibiotics (Amoxicillin) (2022)

Older than or equal to 1 years

2022

  • Antibiotiques_Amoxicilline_2022-FunnelAntibiotiques_Amoxicilline_2022-Funnel
  • Antibiotiques_Amoxicilline_2022-SexratioAntibiotiques_Amoxicilline_2022-Sexratio
  • Antibiotiques_Amoxicilline_2022-BIMAntibiotiques_Amoxicilline_2022-BIM
  • Antibiotiques_Amoxicilline_2022-OccurrenceAntibiotiques_Amoxicilline_2022-Occurrence
  • Antibiotiques_Amoxicilline_2022-RedondanceAntibiotiques_Amoxicilline_2022-Redondance
  • Antibiotiques_Amoxicilline_2022-CheapAntibiotiques_Amoxicilline_2022-Cheap
  • Antibiotiques_Amoxicilline_2022-NomenAntibiotiques_Amoxicilline_2022-Nomen
  • Antibiotiques_Amoxicilline_2022-RegionTrendsAntibiotiques_Amoxicilline_2022-RegionTrends
  • Antibiotiques_Amoxicilline_2022-AgeCVAntibiotiques_Amoxicilline_2022-AgeCV
  • Antibiotiques_Amoxicilline_2022-DotPlotAntibiotiques_Amoxicilline_2022-DotPlot
  • Antibiotiques_Amoxicilline_2022-TrendsAntibiotiques_Amoxicilline_2022-Trends
  • Antibiotiques_Amoxicilline_2022-CarteAntibiotiques_Amoxicilline_2022-Carte


WE ARE INTERESTED IN YOUR OPINION

Do you have any experience in this area ? We listen to you !

Send us an email

   Download the full report
 Download the methodology